JAC Advance Access originally published online on January 28, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 585-591
© 2003 The British Society for Antimicrobial Chemotherapy
Antibacterial poly(D,L-lactic acid) coating of medical implants using a biodegradable drug delivery technology
1 Institut für Experimentelle Onkologie und Therapieforschung; 2 Klinik und Poliklinik für Orthopädie und Sportorthopädie; 3 Institut für Medizinische Statistik und Epidemiologie, der Technischen Universität München, Ismaninger Strasse 22, 81675 Munich, Germany
Received 4 September 2002; returned 16 October 2002; revised 26 November 2002; accepted 26 November 2002
Objectives: Biomaterial-associated bacterial infections present common and challenging complications with medical implants. The purpose of this study was to determine the antibacterial properties of a low molecular weight biodegradable poly(D,L-lactic acid) coating with integrated antibiotics gentamicin and teicoplanin.
Methods: Coating of Kirschner-wires was carried out by a solvent casting technique under aseptic conditions with and without incorporated antibiotics. Release kinetics of gentamicin and teicoplanin were studied in phosphate-buffered saline. Initial bacterial adhesion of Staphylococcus epidermidis on coated and bare implants was determined by radiolabelling and counts of detached viable organisms.
Results: The incorporated antibiotics showed a continuous release over a period of at least 96 h with an initial peak of release in the first 6 h. Attachment of non-viable microorganisms, detected by radiolabelled bacteria, was increased significantly by the polymer coatings (P < 0.05). In contrast, the number of viable bacteria was reduced by the pure polymer (P < 0.01) and further by the polymer–antibiotic combinations (P < 0.05).
Conclusions: Poly(D,L-lactic acid) coating of implants could offer new perspectives in preventing biomaterial-associated infections. Combinations with other drugs to formulate custom-tailored implant surfaces are feasible.
Keywords: polylactide, PDLLA, drug release, Staphylococcus, biomaterial
* Corresponding author. Tel/Fax: +49-89-4140-7242; E-mail: h.gollwitzer{at}lrz.tu-muenchen.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Zilberman, Y. Shifrovitch, M. Aviv, and M. Hershkovitz Structured Drug-eluting Bioresorbable Films: Microstructure and Release Profile J Biomater Appl, March 1, 2009; 23(5): 385 - 406. [Abstract] [PDF]
|
|
|
|
 |
|
 F. D. Matl, A. Obermeier, S. Repmann, W. Friess, A. Stemberger, and K.-D. Kuehn New Anti-Infective Coatings of Medical Implants Antimicrob. Agents Chemother., June 1, 2008; 52(6): 1957 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Jiranek, A. D. Hanssen, and A. S. Greenwald Antibiotic-Loaded Bone Cement for Infection Prophylaxis in Total Joint Replacement J. Bone Joint Surg. Am., November 1, 2006; 88(11): 2487 - 2500. [Abstract] [Full Text] [PDF]
|
|